AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+10%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$253M
AUM Growth
+$253M
(+5.1%)
Cap. Flow
-$2.29M
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
90%
Holding
36
New
8
Increased
2
Reduced
3
Closed
8
Top Buys
| 1 |
Eli Lilly
LLY
|
$38.7M |
| 2 |
Novo Nordisk
NVO
|
$4.11M |
| 3 |
Cytokinetics
CYTK
|
$2.68M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$2.6M |
| 5 |
Insmed
INSM
|
$2.32M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$10.9M |
| 2 |
Roivant Sciences
ROIV
|
$10.7M |
| 3 |
89bio
ETNB
|
$7.19M |
| 4 |
Sarepta Therapeutics
SRPT
|
$6.93M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$6.37M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Novo Nordisk
NVO
$251B
| $74.6M | 21.72% |
721,507
+39,695
| +6% | +$4.11M |
|
|
2
Eli Lilly
LLY
$657B
| $54M | 15.7% |
92,593
+66,400
| +254% | +$38.7M |
|
3
Merck
MRK
$210B
| $35.9M | 10.44% |
329,200
| – | – |
|
4
AbbVie
ABBV
$372B
| $14.1M | 4.09% |
90,821
| – | – |
|
5
argenx
ARGX
$43.6B
| $13M | 3.79% |
34,238
-15,000
| -30% | -$5.71M |
|
6
AstraZeneca
AZN
$248B
| $12.8M | 3.74% |
190,752
| – | – |
|
7
Viking Therapeutics
VKTX
$3.04B
| $7.14M | 2.08% |
383,580
| – | – |
|
8
Axsome Therapeutics
AXSM
$6.05B
| $6.99M | 2.03% |
87,848
| – | – |
|
9
Neurocrine Biosciences
NBIX
$13.8B
| $5.93M | 1.73% |
45,000
| – | – |
|
|
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.98M | 0.87% |
41,600
| – | – |
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.79M | 0.81% |
28,885
-49,580
| -63% | -$4.78M |
|
|
12
Cytokinetics
CYTK
$4.23B
| $2.68M | 0.78% |
+32,113
| New | +$2.68M |
|
|
VRNA
13
Verona Pharma
VRNA
$9.16B
| $2.6M | 0.76% |
+130,790
| New | +$2.6M |
|
14
Protagonist Therapeutics
PTGX
$3.67B
| $2.58M | 0.75% |
112,340
| – | – |
|
15
Vaxcyte
PCVX
$4B
| $2.42M | 0.7% |
38,555
| – | – |
|
|
16
Insmed
INSM
$28.8B
| $2.32M | 0.68% |
+74,936
| New | +$2.32M |
|
17
Ocular Therapeutix
OCUL
$2.12B
| $1.96M | 0.57% |
+440,000
| New | +$1.96M |
|
18
Pliant Therapeutics
PLRX
$101M
| $1.81M | 0.53% |
100,000
| – | – |
|
19
Charles River Laboratories
CRL
$8.04B
| $1.63M | 0.47% |
6,905
| – | – |
|
20
EyePoint Pharmaceuticals
EYPT
$797M
| $1.16M | 0.34% |
+50,000
| New | +$1.16M |
|
21
Waters Corp
WAT
$18B
| $937K | 0.27% |
2,845
| – | – |
|
22
Immunovant
IMVT
$2.56B
| $901K | 0.26% |
+21,397
| New | +$901K |
|
23
RAPT Therapeutics
RAPT
$188M
| $488K | 0.14% |
+19,638
| New | +$488K |
|
24
Biomea Fusion
BMEA
$116M
| $370K | 0.11% |
25,452
| – | – |
|
25
Apogee Therapeutics
APGE
$2.17B
| $290K | 0.08% |
+10,381
| New | +$290K |
|